Journal article

Genetic correlation between amyotrophic lateral sclerosis and schizophrenia

Russell L McLaughlin, Dick Schijven, Wouter van Rheenen, Kristel R van Eijk, Margaret O'Brien, Rene S Kahn, Roel A Ophoff, An Goris, Daniel G Bradley, Ammar Al-Chalabi, Leonard H van den Berg, Jurjen J Luykx, Orla Hardiman, Jan H Veldink

Nature Communications | NATURE PUBLISHING GROUP | Published : 2017

University of Melbourne Researchers

Grants

Awarded by Research Foundation KU Leuven


Awarded by European Community's Health Seventh Framework Programme (FP7)


Awarded by MRC


Awarded by Alzheimer's Research UK


Awarded by Wellcome Trust


Awarded by German Federal Ministry of Education and Research: Competence Network Dementia


Awarded by NIH/NIA


Awarded by NIA


Awarded by AGES


Awarded by NHLBI


Awarded by Alzheimer's Association


Funding Acknowledgements

We acknowledge helpful contributions from Mr Gert Jan van de Vendel in the design and execution of PRS analyses. This study received support from the ALS Association; Fondation Thierry Latran; the Motor Neurone Disease Association of England, Wales and Northern Ireland; Science Foundation Ireland; Health Research Board (Ireland), The Netherlands ALS Foundation (Project MinE, to J.H.V., L.H.v.d.B.), the Netherlands Organisation for Health Research and Development (Vici scheme, L.H.v.d.B.) and ZonMW under the frame of E-Rare-2, the ERA Net for Research on Rare Diseases (PYRAMID). Research leading to these results has received funding from the European Community's Health Seventh Framework Programme (FP7/2007-2013). A.G. is supported by the Research Foundation KU Leuven (C24/16/045). A.A.-C. received salary support from the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit and Biomedical Research Centre in Mental Health at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Samples used in this research were in part obtained from the UK National DNA Bank for MND Research, funded by the MND Association and the Wellcome Trust. We acknowledge sample management undertaken by Biobanking Solutions funded by the Medical Research Council (MRC) at the Centre for Integrated Genomic Medical Research, University of Manchester. This is an EU Joint Programme-Neurodegenerative Disease Research (JPND) Project (STRENGTH, SOPHIA). In addition to those mentioned above, the project is supported through the following funding organizations under the aegis of JPND: UK, Economic and Social Research Council; Italy, Ministry of Health and Ministry of Education, University and Research; France, L'Agence nationale pour la recherche. The work leading up to this publication was funded by the European Community's Health Seventh Framework Programme (FP7/2007-2013; Grant Agreement Number 2,59,867). We thank the International Genomics of Alzheimer's Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the control subjects, the patients, and their families. The i-Select chips was funded by the French National Foundation on Alzheimer's disease and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Universite de Lille 2 and the Lille University Hospital. GERAD was supported by the MRC (Grant No. 5,03,480), Alzheimer's Research UK (Grant No. 5,03,176), the Wellcome Trust (Grant No. 082604/2/07/Z) and German Federal Ministry of Education and Research: Competence Network Dementia Grant no. 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA Grant R01 AG033193 and the NIA AG081220 and AGES contract N01-AG-12,100, the NHLBI Grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA Grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association Grant ADGC-10-196728.r The Project MinE GWAS Consortium included contributions from the PARALS registry, SLALOM group, SLAP registry, FALS Sequencing Consortium, SLAGEN Consortium and NNIPPS Study Group; the Schizophrenia Working Group of the Psychiatric Genomics Consortium included contributions from the Psychosis Endophenotypes International Consortium and Wellcome Trust Case-control Consortium. Members of these eight consortia are listed in Supplementary Note 2.